IDXX stock forecast, quote, news & analysis
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock... Show more
IDEXX Laboratories (IDXX) Stock Analysis: AI-Driven Diagnostics and inVue Dx Momentum Underpin Growth Narrative
Key Takeaways
- IDEXX Laboratories shares have traded in a relatively narrow range over the past 30 days, hovering near $564 — a level roughly flat compared to mid-June — reflecting mixed analyst sentiment and a consolidating market.
- The company posted strong first-quarter 2026 results, with EPS of $3.47 beating consensus estimates of $3.41 and revenue of $1.14 billion rising 14.3% year-over-year, driven by double-digit Companion Animal Group Diagnostics recurring revenue growth.
- IDEXX raised its full-year 2026 guidance to revenue of $4.675–$4.760 billion and EPS of $14.45–$14.90, supported by expanding instrument placements, innovation-driven testing utilization, and modestly improving clinical visit trends.
- Wall Street maintains a Moderate Buy consensus with an average price target of roughly $751, though several firms — including BofA, UBS, and Stifel — have trimmed targets, and Wall Street Zen recently downgraded the stock to Hold.
- The upcoming Q2 2026 earnings report on August 4 and the 2026 Investor Day on August 13 are key near-term catalysts that could reshape investor sentiment.
- The inVue Dx platform and Cancer Dx test expansion represent central elements of IDEXX's AI-powered innovation strategy, with the company targeting approximately 5,500 inVue Dx placements in 2026.
Current Market Snapshot
IDEXX Laboratories shares have exhibited rangebound behavior in recent weeks, with the stock trading near $564 as of mid-July 2026 — essentially flat relative to the mid-June closing level around $562. The stock continues to trade below its 200-day moving average of approximately $599 and well beneath its 52-week high of $769.98 reached in the prior year. The 50-day moving average sits near $554, providing nearby technical support. With a market capitalization of roughly $44.8 billion, a price-to-earnings ratio near 42, and a beta of 1.55, IDXX retains a premium valuation that reflects its leadership in the veterinary diagnostics space. Broader market rotation within healthcare and animal health names, combined with analyst recalibration of price targets, has contributed to a consolidative tone. Institutional ownership remains exceptionally high at 87.84%, underscoring long-term conviction despite near-term macro uncertainty.
IDEXX Laboratories (IDXX) Business Overview and Competitive Position
IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, developing and manufacturing diagnostic products, instruments, and software solutions for the companion animal veterinary, livestock, poultry, dairy, and water testing markets. Headquartered in Westbrook, Maine, and employing approximately 11,000 people, IDEXX serves customers across more than 175 countries. Its Companion Animal Group — the core growth engine — provides in-clinic chemistry and hematology analyzers, rapid assay tests, reference laboratory services, and cloud-based veterinary practice management software. The company's flagship IDEXX VetLab suite, the recently launched inVue Dx cellular analysis platform, and the Cancer Dx early-detection test anchor a broad innovation portfolio that leverages artificial intelligence and machine learning. IDEXX's competitive moat is reinforced by a large installed base of proprietary instruments, high consumables pull-through, a global reference lab network, and deep integration between diagnostic hardware and practice software. With a debt-to-equity ratio of just 0.19 and a net margin of roughly 25%, the company combines financial discipline with sustained R&D investment.
Recent Developments Driving IDXX
The most significant development in recent weeks has been the recalibration of analyst sentiment. On July 12, Wall Street Zen downgraded IDXX from Buy to Hold, and Weiss Ratings lowered its rating to Hold (c) on July 14. These moves followed earlier price target reductions from BofA Securities (to $660 from $790), UBS (to $640 from $730), and Stifel (to $675 from $775), though all three maintained their respective ratings. Despite these cuts, the average analyst target of approximately $751 implies roughly 33% upside from current levels, and the consensus recommendation remains Moderate Buy with seven Buy ratings and four Holds.
On the operational front, IDEXX's first-quarter 2026 results — reported on May 5 — demonstrated robust execution. Companion Animal Group Diagnostics recurring revenue grew 14% as reported and 11% organically. IDEXX VetLab consumables surged 20% as reported, benefiting from a 12% expansion in the global premium instrument installed base. The company placed 1,100 inVue Dx systems in Q1, on track toward the full-year target of approximately 5,500. At the Stifel Jaws & Paws Conference in late May, new CEO Mike Erickson emphasized the transformative potential of AI across IDEXX's portfolio — from embedded diagnostics in inVue Dx and SediVue Dx to internal software development productivity — and described the inVue Dx launch as one of the most successful in company history.
Institutional activity has been mixed: KBC Group NV reduced its position by 44.2% in Q1, and CalPERS trimmed its stake by 3.7%, while Candriam S.C.A. and Mediolanum International Funds increased their holdings by 26.6% and 22%, respectively. The upcoming Q2 2026 earnings release on August 4 — with consensus EPS of approximately $3.95 — and the 2026 Investor Day on August 13 are poised to provide critical updates on inVue Dx traction, Cancer Dx expansion, and the broader innovation roadmap.
Trending AI Robots
Investors navigating the shifting landscape of stocks like IDEXX Laboratories increasingly turn to AI-driven tools for actionable insights. Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots from a universe of hundreds of automated strategies trading thousands of tickers. These bots employ diverse methodologies — ranging from momentum-based swing trading to longer-term trend-following approaches — and are continuously evaluated against real-time performance benchmarks. Only the most relevant and consistently strong-performing bots appear in this section, offering traders a filtered view of AI-powered strategies active in current market conditions. Whether your focus is on healthcare, technology, or broad-market ETFs, exploring the Trending AI Robots page can help identify data-driven approaches aligned with your trading objectives.
2026 Outlook and What Investors Should Watch
IDEXX enters the second half of 2026 with a raised full-year outlook and multiple catalysts on the horizon. The Q2 earnings report on August 4 will be scrutinized for inVue Dx placement momentum, consumables pull-through rates, and any updated commentary on companion animal clinical visit trends — a key macro variable that management has modestly revised to negative 1.5% from negative 2% for the full year. The August 13 Investor Day is expected to provide deeper visibility into the product pipeline, including the broader launch of inVue Dx Fine Needle Aspirate for cancer evaluation, the planned addition of mast cell tumor detection to Cancer Dx, and the mysterious MilQ-ID trademark that management has described as potentially transformative.
Analysts project full-year EPS of approximately $14.68 and forward revenue approaching $4.70 billion, with fiscal 2027 EPS estimates climbing toward $16.53. Key risks include persistent pressure on veterinary clinic visit volumes — particularly among lower-income pet owners — foreign exchange headwinds, potential competitive encroachment in point-of-care diagnostics, and the stock's premium valuation, which leaves limited room for execution missteps. On the upside, accelerating adoption of AI-enabled diagnostic platforms, international market penetration, and menu expansion across the inVue Dx ecosystem could provide sustained growth tailwinds. With a consensus price target well above current trading levels, the burden of proof rests on IDEXX's execution through the remainder of 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IDXX's Stochastic Oscillator remains in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
IDXX moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
IDXX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXX as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IDXX turned negative on July 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for IDXX crossed bearishly below the 50-day moving average on July 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IDXX entered a downward trend on July 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.169) is normal, around the industry mean (13.281). P/E Ratio (40.927) is within average values for comparable stocks, (151.072). IDXX's Projected Growth (PEG Ratio) (3.564) is slightly higher than the industry average of (1.664). IDXX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (10.081) is also within normal values, averaging (8.152).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties